Venous Thromboembolism News and Research

RSS

Partnership for Patients initiative participants launch sprint program to prevent pressure ulcers

Hospitals participating in the Partnership for Patients initiative have launched a program to prevent pressure ulcers.

16 May 2012

EKOS launches two landmark clinical studies on pulmonary embolism

EKOS Corporation today announced the launch of two more landmark clinical studies named SEATTLE I & II, intended to further establish the safety and efficacy of its unique, ultrasound-accelerated thrombolysis in treating patients with life-threatening pulmonary embolism.

3 May 2012

U-M study: 1 in 84 high-risk patients suffer VTE after outpatient surgery

A University of Michigan Health System study examined who's having outpatient surgery in the U.S. today, and showed 1 in 84 highest-risk patients suffers a dangerous blood clot after surgery.

25 Apr 2012

ASH report urges federal agencies to invest in 7 distinct areas of research

The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.

25 Apr 2012

Orthopaedic research studies in the Journal of Bone and Joint Surgery

Below are highlights of orthopaedic research studies appearing in the April 18th issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issue's full Table of Contents.

21 Apr 2012

Bayer announces updated labels for drospirenone-containing COCs in the U.S.

In agreement with the U.S. Food and Drug Administration (FDA), Bayer HealthCare Pharmaceuticals Inc. today announced that it has updated the labels for its drospirenone-containing combination oral contraceptives (COCs) in the United States.

11 Apr 2012

Infections in older adults may increase risk of hospitalization for dangerous blood clots

Research shows older adults who get infections of any kind - such as urinary, skin, or respiratory tract infections - are nearly three times more likely to be hospitalized for a dangerous blood clot in their deep veins or lungs, University of Michigan Health System research shows.

4 Apr 2012

Rivaroxaban found safe and effective in pulmonary embolism

Rivaroxaban has been found to be effective in the prevention of venous thromboembolism (VTE) after orthopedic surgery, for the prevention of stroke in AF (Atrial fibrillation) patients, and as additional therapy to conventional antiplatelet therapy in ACS (Acute coronary syndrome) patients.

27 Mar 2012

Rivaroxaban safer, effective than standard therapy in treating PE

A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism - a blockage of lung blood vessels usually caused by a clot - and showed comparable efficacy, according to data from the EINSTEIN-PE trial presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

Maturitas publishes EMAS' clinical guide on SERMs against postmenopausal osteoporosis

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of an important clinical guide from the European Menopause and Andropause Society (EMAS) in the February issue of Maturitas.

29 Feb 2012

Steady increase in Low Molecular Weight Heparin use for blood clots: Study

The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado.

15 Feb 2012

New guidelines for travellers to avoid DVT on long flights

New guidelines for travellers have been issued. Experts warn that those with a higher risk of serious blood clots who opt for the window seat on flights longer than four hours are potentially putting themselves in danger. People who should be most concerned are those who have recently had surgery, cancer patients, those with limited mobility, the severely obese, and travellers over 70. However, healthy women on the pill and those who are pregnant should also be careful, according to the guidelines by the American College of Chest Physicians.

7 Feb 2012

Enrollment complete in ThromboGenics, BioInvent TB-402 Phase IIb trial on VTE

ThromboGenics NV and co-development partner BioInvent International announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 for the prophylaxis of venous thromboembolism (VTE) after total hip surgery. The trial has recruited patients from 36 centers across Europe.

17 Dec 2011

Research examines novel treatment techniques for hemophilia B, VTE

Bleeding and clotting disorders affect a large number of patients annually and, while accurate diagnosis is important, timely and effective treatment for these disorders is key, as they have the potential to quickly become life-threatening. Research examining novel treatment techniques for bleeding and clotting disorders will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

Public health officials should address needs of people with blood disorders

Public health should focus not only on reducing the burden of common diseases but also address the needs of people with blood disorders , experts say in a supplement to December's American Journal of Preventive Medicine.

16 Nov 2011

Merck's NEXPLANON 68 mg now available in the U.S.

Merck today announced that NEXPLANON (etonogestrel implant) 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States.

10 Nov 2011

Oral hormonal contraceptives linked to blood clots: Study

A new study has shown that women who use new type of contraceptive pills are twice as likely to develop life threatening blood clots as those who take older versions. Oral hormonal contraceptives have been known to increase the risk of a blood clot in deep leg veins, known as venous thromboembolism (VTE). These can prove fatal if they travel to the lungs. But, researchers at the University of Copenhagen, Denmark, found the “third-generation” pills are doubly harmful than the older versions.

30 Oct 2011

Enoxaparin can reduce risk of VTE in plastic surgery patients

For plastic surgery patients at high risk, treatment with the anticoagulant (blood-thinning) drug enoxaparin can reduce the risk of serious blood clot-related complications called venous thromboembolism (VTE), reports a study in the November issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

28 Oct 2011

VDC and P.A.D. Coalition present annual research awards at VDF's eighth annual meeting

The Venous Disease Coalition (VDC) and Peripheral Arterial Disease Coalition presented their annual research awards at the Vascular Disease Foundation's eighth annual meeting in Washington.

30 Sep 2011

One in five cancer patients more likely to develop venous thromboembolism

An analysis of more than 30,000 cancer patients has shown that blood clots are a more common complication than doctors may realize, causing additional hospitalizations and driving up the cost of care, according to a study led by a Duke Cancer Institute researcher.

21 Sep 2011